Company: CSTL
Filing Date: 2025-04-09
Form Type: DEF 14A
Source: 0001447362-25-000054
Chunk: 47

Company: CASTLE BIOSCIENCES INC
Filing Date: 2025-04-09
Form: DEF 14A
Chunk 47
---
 IDgenetix®

#### 46Castle Biosciences 2025 Proxy Statement

#### Compensation Discussion & Analysis

#### Our Test Portfolio
Our portfolio consists of test offerings to aid clinicians in the diagnosis and treatment of cancers or precancerous diagnoses in the fields of dermatology, gastroenterology and ophthalmology and a PGx test to guide optimal drug treatment for patients diagnosed with depression, anxiety and other mental health conditions.

Maintaining commercial success for our existing test portfolio requires generating ongoing evidence, such as clinical performance, clinical use documentation, to support appropriate clinician adoption, reimbursement success and guideline inclusion. The clinical validity and utility of our test portfolio is supported by peer-reviewed publications and ongoing clinical studies. Collectively, approximately 157 peer-reviewed articles have been published demonstrating the analytical validity, clinical validity and clinical utility of the tests in our portfolio.

#### 2024 Performance Highlights
• $332 million in revenue, 51% year-over-year growth

• 96,071 delivered test reports, 36% year-over-year growth

• As of December 31, 2024, cash and cash equivalents of $119.7 million and $173.4 million of marketable investment securities

• Publication of 157 peer-reviewed studies across all franchises to date

#### 2024 Compensation Highlights
• Short-Term Incentive Plan - The Company achieved 128.8% of corporate performance goals. As a result, the bonus paid to our CEO was 128.8% of the target bonus opportunity and the average bonuses paid to the other NEOs was 128.0% of the target bonus opportunity.

• Long-Term Incentive Plan - The timing of the grant of equity awards to our executive officers was shifted from the fourth quarter of our fiscal year to the first quarter of our subsequent fiscal year to ensure better alignment with the Company’s full fiscal year’s performance before making pay decisions for the following year. As a result, no annual equity awards were granted in 2023. We resumed granting our annual equity awards in Q1 2024. We expect to maintain this cycle moving forward to better align with the Company’s fiscal year results.

• Performance-Based Equity - Based on Stockholder feedback, a significant portion of executive compensation will be “at-risk” and continue to be performance-based. In 2024 and 2025, the performance-based equity awards represented 50% of the total equity award value for our CEO and approximately 25% of our other NEOs based on the grant